GAVRETO Now approved

GAVRETO™ is a once-daily oral targeted therapy for people living with RET-positive non–small cell lung cancer (NSCLC) that has spread to other parts of the body, or metastasized.

RET+=rearranged during transfection positive.

Ask your doctor if GAVRETO
could be right for you.

RET+=rearranged during transfection positive.